About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Efficacy of QAX576 in Asthma | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT01130064

Efficacy of QAX576 in Asthma

The purpose of this study is to investigate the efficacy of 24 weeks intravenous treatment with QAX576 in patients with persistent asthma not adequately controlled with inhaled corticosteroids and lon...

Lead sponsor: Novartis Pharmaceuticals•10 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Male and female patients
•Female patients must be surgically sterilized or postmenopausal
•Male patients must use two forms of contraception
•Body mass index must be between 18 and 39 kg/m2
•Diagnosis of asthma for at least one year, which is not adequately controlled by inhaled corticosteroids and long acting beta-2 agonists

Exclusion Criteria

•Smoking history \>10 pack-years
•Patients with a diagnosis of chronic obstructive pulmonary disease (COPD)
•Patients who have experienced a severe asthma attack/exacerbation requiring systemic corticosteroids or an increase in maintenance doses, within 6 weeks of screening
•Patients who have had a respiratory tract infection within 6 weeks prior to screening
•History of schistosomiasis, within 6 months of screening, or traveling to a country endemic with schistosomiasis within 6 months of completing the study

Related studies

RECRUITINGPhase 2

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

NCT07301736 · Asthma

Remote Anxiety Management for ICS-resistant Asthma Study

NCT06732141 · Asthma

RECRUITINGPhase 2

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263 · Asthma

Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis

NCT07245576 · Asthma, COPD

Obstructive Sleep Apnoea and Difficult Asthma (OSADA)

NCT07160868 · Asthma (Diagnosis), OSA - Obstructive Sleep Apnea, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 19, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment259

Start dateMay 2010

Last updatedDec 19, 2020

Condition

Locations shown

Novartis Investigative Site

Phoenix, Arizona

Novartis Investigative Site

Huntington Beach, California

Novartis Investigative Site

Owensboro, Kentucky

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2020Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions